HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Cidara Therapeutics (NASDAQ:CDTX) and maintained a $6 price target on the stock.
December 07, 2023 | 11:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cidara Therapeutics has been given a reiterated Buy rating and a maintained price target of $6 by HC Wainwright & Co. analyst Ed Arce.
The reiteration of a Buy rating and the maintenance of a $6 price target by a reputable analyst could lead to increased investor confidence in Cidara Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100